331. 特発性多中心性キャッスルマン病 Idiopathic multicentric castleman disease Clinical trials / Disease details

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

diseases per page:

Showing 1 to 10 of 33 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05345522 (ClinicalTrials.gov)	April 18, 2022	19/4/2022	A Study of Anti-IL-6R mAb Injection in Patients With iMCD	A Single-arm, Open-label, Multi-center Phase ?a Clinical Study to Evaluate the Efficacy and Safety o ...	Idiopathic Multicentric Castleman's Disease	Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg;B ...	Beijing VDJBio Co., LTD.	NULL	Recruiting	18 Years	N/A	All	9	Phase 2	China
2	ChiCTR2100048364	2021-09-01	2021-07-06	A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castlema ...	A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castlema ...	Castleman disease	Treatment group:Rituximab+lenalidomide;	Department of Hematology, Jiangsu Provincial People's Hospital	NULL	Pending	14	90	Both	Treatment group:20;	Phase 4	China
3	NCT04585893 (ClinicalTrials.gov)	June 22, 2021	10/9/2020	Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi	LCCC 1950 - Rituximab for Multicentric Castleman Diseasein Malawi, A Single-Arm Phase II Safety/Effi ...	Multicentric Castleman Disease	Drug: Rituximab;Drug: Etoposide	UNC Lineberger Comprehensive Cancer Center	Fogarty International Center of the National Institute of Health	Recruiting	18 Years	N/A	All	27	Phase 2	Malawi
4	NCT04838860 (ClinicalTrials.gov)	March 31, 2021	25/2/2021	Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease	A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric ...	Idiopathic Multicentric Castleman's Disease	Drug: Siltuximab	EusaPharma (UK) Limited	NULL	Terminated	12 Years	N/A	All	22	Phase 2	United States
5	NCT04743687 (ClinicalTrials.gov)	January 1, 2021	3/2/2021	Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial	The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castlema ...	Idiopathic Multicentric Castleman's Disease	Drug: Zanubrutinib	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	China
6	JPRN-jRCT2071190029	25/05/2020	09/10/2019	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resi ...	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resi ...	idiopathic multicentric Castleman's disease Castleman's disease	Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily	Kawakami Atsushi	NULL	Complete	>= 18age old	Not applicable	Both	20	Phase 2	Japan
7	NCT03864419 (ClinicalTrials.gov)	October 24, 2019	1/3/2019	Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in U ...	A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemoth ...	Burkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell Lymphoma	Biological: Rituximab and Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotre ...	Fred Hutchinson Cancer Center	NULL	Recruiting	2 Years	N/A	All	40	Phase 1	Uganda;United States
8	NCT03933904 (ClinicalTrials.gov)	September 25, 2019	29/4/2019	Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease	A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic M ...	Castleman Disease;Castleman's Disease, Multicentric	Drug: Sirolimus	University of Pennsylvania	NULL	Recruiting	2 Years	80 Years	All	24	Phase 2	United States
9	NCT03982771 (ClinicalTrials.gov)	January 1, 2019	3/5/2019	BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)	Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Cast ...	Idiopathic Multicentric Castleman's Disease	Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethason	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	China
10	NCT03043105 (ClinicalTrials.gov)	January 1, 2017	31/1/2017	TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a ...	Multicentric Castleman Disease	Drug: Thalidomide , cyclophosphamide and prednisone	Peking Union Medical College Hospital	NULL	Active, not recruiting	18 Years	N/A	All	25	Phase 2	China

First Previous1 2 3 4Next Last